Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Data Back Keryx's Plan To Expand Auryxia Market

This article was originally published in Scrip

Executive Summary

Keryx Biopharmaceuticals Inc. had a rough first year of sales for its oral, iron-based phosphate binder Auryxia (ferric citrate), but the company and it investors have high hopes that new Phase III data will support approval for a second indication that could double the drug's market.


Related Content

New US Indication May Help Finally Get Keryx' Auryxia Off The Ground
Ten Approvals To Look Out For In Q4



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts